glp-1 vs gip-1 The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology GLP-1 vs. GLP-1 + GIP:

In a trial of 21 healthy seniors confined to bed rest for 10 days, it was well-tolerated and demonstrated an ability to reduce muscle atrophy compared to a placebo

Mounjaro and Vision Changes 2026 Update July 2026: There are currently 146 pending claims in the MDL for patients alleging that GLP-1 drugs, including Mounjaro, led them to develop NAION (vision loss)

Cardiovascular Health: The SELECT trial showed semaglutide lowered major cardiovascular events by 20% in those with obesity and heart disease, regardless of diabetes

In week two, after three days of sardine fasting, his glucose dropped to 140 and his ketones rose to 2.0

Patients carrying specific alleles may experience more pronounced blood pressure responses, information that helps your provider personalize your dose and monitoring plan